{
    "guideline_id": "2024CSCO恶性血液病诊疗指南.txt",
    "cancer_info": {
        "cancer_name": "Hematologic Malignancies"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Ph-negative acute lymphoblastic leukemia (ALL)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Induction: VDCLP ± anti-CD20 monoclonal antibody (e.g., rituximab). Post-remission: Chemotherapy, CAR-T, or allogeneic transplant based on risk stratification.",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Ph-positive acute lymphoblastic leukemia (ALL)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Induction: TKI (dasatinib/nilotinib) + chemotherapy. Post-remission: TKI + blinatumomab → maintenance therapy.",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Non-APL acute myeloid leukemia (AML), age ≤60 years, fit patients",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "DA/IA regimen ± targeted agents (e.g., FLT3 inhibitor for FLT3-mutated cases or venetoclax).",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "FLT3",
                    "status": "Mutated",
                    "testing_guidance": "Testing required to guide FLT3 inhibitor use (e.g., gilteritinib)"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Non-APL acute myeloid leukemia (AML), age ≤60 years, unfit patients",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Azacitidine + venetoclax.",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Non-APL acute myeloid leukemia (AML), age >60 years",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Venetoclax combined with hypomethylating agents (azacitidine or decitabine).",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Acute promyelocytic leukemia (APL)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Induction: ATRA + arsenic trioxide ± anthracyclines. High-risk group (WBC ≥10×10⁹/L) requires intensive chemotherapy.",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Chronic lymphocytic leukemia (CLL), without del17p/TP53 mutation",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Zanubrutinib (priority) or chlorambucil + anti-CD20 monoclonal antibody.",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "del17p or TP53",
                    "status": "Negative",
                    "testing_guidance": "Testing required for stratification; use FISH/NGS to detect mutation status."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Chronic lymphocytic leukemia (CLL), with del17p/TP53 mutation",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Zanubrutinib or ibrutinib.",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "del17p or TP53",
                    "status": "Positive",
                    "testing_guidance": "Testing required for stratification; use FISH/NGS to detect mutation status."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Chronic myeloid leukemia (CML), chronic phase, low-risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Imatinib.",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Chronic myeloid leukemia (CML), chronic phase, intermediate-high risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Second-generation TKI (e.g., dasatinib, nilotinib).",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Chronic myeloid leukemia (CML), with T315I mutation",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Olverembatinib or ponatinib.",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "T315I",
                    "status": "Positive",
                    "testing_guidance": "Testing required for mutation detection; use NGS or targeted sequencing."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Multiple myeloma (MM), transplant-eligible",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "VRd (bortezomib + lenalidomide + dexamethasone) ± daratumumab, followed by autologous stem cell transplant (ASCT).",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Multiple myeloma (MM), transplant-ineligible",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "DRd (daratumumab + lenalidomide + dexamethasone).",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Primary plasma cell leukemia (pPCL)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Low-risk: Proteasome inhibitor-based triple-drug regimen (e.g., VRd). High-risk: Intensive chemotherapy (e.g., HyperCVAD) or CAR-T; if eligible, double ASCT or allogeneic HSCT.",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "del17p or TP53",
                    "status": "Mutated",
                    "testing_guidance": "Testing required for risk stratification; indicates poor prognosis and guides therapy intensity."
                },
                {
                    "biomarker_name": "t(11;14)",
                    "status": "Positive",
                    "testing_guidance": "Testing via FISH; predicts sensitivity to BCL2 inhibitors (e.g., venetoclax)."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Systemic light-chain amyloidosis (AL)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Low-risk: CyBorD (bortezomib + cyclophosphamide + dexamethasone). High-risk: Daratumumab-based regimens; if eligible, ASCT.",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Waldenström macroglobulinemia (WM)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Asymptomatic: Observation. Symptomatic: Rituximab ± bendamustine. High-risk: BTK inhibitor (ibrutinib/zanubrutinib) + rituximab.",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "MYD88 L265P",
                    "status": "Positive",
                    "testing_guidance": "Testing required for diagnosis; >90% prevalence, guides BTK inhibitor use."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Myelodysplastic syndromes (MDS), low-risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "EPO (if EPO <500 IU/L) or lenalidomide (for del5q). Supportive care with traditional Chinese medicine.",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation for EPO/lenalidomide",
            "evidence_level": ""
        },
        {
            "clinical_context": "Myelodysplastic syndromes (MDS), high-risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Azacitidine or decitabine. If age ≤70 and no severe comorbidities, allogeneic HSCT.",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "del17p or TP53",
                    "status": "Mutated",
                    "testing_guidance": "Testing required; indicates high risk and poor response to standard therapy."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Polycythemia vera (PV)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Low-risk: Low-dose aspirin + phlebotomy. High-risk: Cytoreductive therapy (hydroxyurea, interferon-α) or ruxolitinib.",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "JAK2 V617F",
                    "status": "Mutated",
                    "testing_guidance": "Testing required for diagnosis; >95% prevalence, guides JAK inhibitor use."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Essential thrombocythemia (ET)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Low-risk: Observation. High-risk: Cytoreductive therapy (hydroxyurea, interferon-α).",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "JAK2/CALR/MPL",
                    "status": "Mutated",
                    "testing_guidance": "Testing required for diagnosis; CALR/MPL mutations indicate better prognosis."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Primary myelofibrosis (PMF)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Symptomatic splenomegaly or constitutional symptoms: Ruxolitinib. High-risk: Allogeneic HSCT or gilteritinib (for ruxolitinib resistance).",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "JAK2 V617F",
                    "status": "Mutated",
                    "testing_guidance": "Testing required; target for JAK inhibitors."
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Biomarkers guide prognosis, risk stratification, and targeted therapy selection. Key examples: del17p/TP53 mutations indicate high risk and poor prognosis in MM, pPCL, and MDS; FLT3 mutations in AML predict response to FLT3 inhibitors; MYD88 L265P in WM is diagnostic and guides BTK inhibitor use; JAK2 V617F in MPNs (PV, ET, PMF) is a driver mutation and target for JAK inhibitors; t(11;14) in pPCL/MM predicts sensitivity to BCL2 inhibitors; CALR/MPL mutations in ET/PMF confer better prognosis; SF3B1 mutations in MDS indicate favorable outcomes."
    },
    "tcm_recommendations": [
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "Compound Huangdai Tablet (复方黄黛片) at 60mg/kg/day orally, combined with ATRA for induction/consolidation therapy in APL.",
            "recommendation_grade": "Level I Recommendation"
        },
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "Traditional Chinese medicine as supportive care for anemia in low-risk MDS.",
            "recommendation_grade": "Level II Recommendation"
        }
    ]
}